California State Teachers Retirement System increased its position in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 6.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,139 shares of the company’s stock after purchasing an additional 1,548 shares during the period. California State Teachers Retirement System’s holdings in Jounce Therapeutics were worth $213,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Candriam Luxembourg S.C.A. bought a new stake in Jounce Therapeutics during the third quarter worth approximately $2,878,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Jounce Therapeutics by 8.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 309,384 shares of the company’s stock valued at $2,525,000 after buying an additional 25,065 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Jounce Therapeutics by 3.4% in the second quarter. Jacobs Levy Equity Management Inc. now owns 180,748 shares of the company’s stock valued at $1,247,000 after buying an additional 5,999 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Jounce Therapeutics by 29.1% in the second quarter. Sei Investments Co. now owns 137,912 shares of the company’s stock valued at $949,000 after buying an additional 31,080 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Jounce Therapeutics by 5.5% in the second quarter. Bank of Montreal Can now owns 118,074 shares of the company’s stock valued at $753,000 after buying an additional 6,199 shares in the last quarter. 63.62% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have issued reports on JNCE. Raymond James cut Jounce Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday, November 2nd. BidaskClub raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Jounce Therapeutics in a research report on Friday, December 4th. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research report on Thursday, November 12th. Finally, Roth Capital lowered their price objective on shares of Jounce Therapeutics from $28.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, November 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. Jounce Therapeutics presently has an average rating of “Hold” and a consensus target price of $11.56.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.36). On average, equities analysts anticipate that Jounce Therapeutics, Inc. will post -2.21 earnings per share for the current year.
In other news, major shareholder Rock Ventures Ii L.P. Third sold 15,000 shares of the business’s stock in a transaction on Thursday, November 19th. The shares were sold at an average price of $7.01, for a total value of $105,150.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 43.96% of the stock is currently owned by insiders.
Jounce Therapeutics Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer.
Read More: What is the Stochastic Momentum Index (SMI)?
Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics, Inc. (NASDAQ:JNCE).
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.